Recordati SpA (REC) Earnings Reveal 9M Revenue of EU1.96B and EBITDA of EU743.9M

Recordati SpA on Smartkarma

Analysts on Smartkarma, like Baptista Research, are bullish on Recordati SpA. In their report titled “Recordati – Dual Engine Strategy Powers Rare Disease Dominance & SPC Stability!” they highlight the company’s strong performance in the first quarter of 2025. Recordati saw a remarkable 11.9% growth in net revenue, reaching EUR 680 million compared to the previous year. This growth was driven by progress in both its specialty and primary care (SPC) and rare diseases segments, with SPC increasing by 5% and rare diseases by 11.5% on a like-for-like constant exchange rate basis.

A look at Recordati SpA Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Recordati SpA, a pharmaceutical manufacturer, has shown a promising long-term outlook based on the Smartkarma Smart Scores. With a Growth score of 4 and a Resilience score of 4, the company demonstrates strong potential for both expansion and stability in the market. These scores indicate that Recordati SpA is well-positioned to continue growing and withstand market challenges, making it an attractive prospect for investors seeking steady returns.

Additionally, the company receives a Dividend score of 3, suggesting that it offers a moderate level of dividend payouts to shareholders. Coupled with a Momentum score of 3, which reflects the company’s current market performance, Recordati SpA presents a balanced investment opportunity that combines growth potential with dividends. Overall, the Smartkarma Smart Scores paint a positive picture for Recordati SpA, highlighting its growth prospects, resilience, and stability in the pharmaceutical industry.

Summary: Recordati SpA is a pharmaceutical company that researches, develops, manufactures, and markets prescription and non-prescription pharmaceuticals, pharmaceutical chemicals, therapeutic products, and rare disease treatments globally.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma